Abstract: The invention provides compositions and methods useful for the treatment and prevention of conditions associated with myocardial infarction.

Abstract: The invention provides compositions and methods useful for the treatment and prevention of conditions associated with myocardial infarction.

Abstract: The present invention is a chemical compound of formula (I) or a pharmaceutically acceptable salts, solvates and esters thereof, wherein R1 to R4, A1, A2 m and n are as described in the specification.

Abstract: The present invention relates to novel gene and polypeptide targets identified in skeletal muscle for screening of compounds that may be useful for the prevention and treatment of obesity.

Abstract: The present invention relates to novel targets for identifying compounds that may be useful for the prevention and treatment of obesity.

Abstract: The present invention is a chemical compound of formula (I) 1

Abstract: The present invention is a chemical compound of formula (I) or a pharmaceutically acceptable salt, solvate and ester thereof, wherein R1 to R4 and n are as defined in the specification. A compound of formula 1 is useful as a pharmaceutical composition for the treatment or prevention of disorders of the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes, obesity and sleep apnoea.

Abstract: The present invention relates to the use of Soraphen derivatives and pharmaceutically acceptable esters thereof, for the treatment and/or prophylaxis of diseases which are associated with ACC&bgr; activity and/or fatty acid oxidation such as diabetes, obesity and dyslipidemia.

Abstract: The present invention is a chemical compound of formula (I) 1

Abstract: The present invention is a chemical compound of formula (I) 1

Abstract: The present invention provides medicinal compounds that are characterized by a cyclic moiety (A) linked through a carboxamido group (more specifically, a carbamate group or a urea group) to another cyclic moiety (B) which is in turn linked to another, N-substituted carboxamido group. These compounds can be used an anti-inflammatory and immunosuppressive agents, as demonstrated by their inhibition of the production of IL-1.beta. in vitro and TNF.alpha. in vivo.

Abstract: Analogues of the active metabolite of leflunomide, and to the use thereof as immunosuppressive and/or antinflammatory agents.

Abstract: Imidazole derivatives having A II antagonist activity, of Formula I, the processes for the preparation thereof, pharmaceutical compositions containing them and the use thereof as therapeutic agents. The described compounds having A II antagonist activity can be used in various cardiovascular disorders.

Abstract: Compounds of general formula (I) ##STR1## wherein E is O or S; R is C.sub.1 -C.sub.5 straight, branched or cyclic alkyl or C.sub.2 -C.sub.5 alkenyl; X can be H, F, Cl, Br, I, CF.sub.3 ; n is an integer 1 to 4; m is an integer 0 to 4; A and B are 5- or 6- membered aromatic carbocyclic rings optionally containing one or more heteroatoms selected from N, O, S and carrying the substituents R.sub.1, R.sub.2 and R.sub.3, respectively; R.sub.1 can be hydrogen, halogen, C.sub.1 -C.sub.4 alkoxycarbonyl, a sulfonic group or a tetrazole group of formula ##STR2## wherein R.sub.4 can be hydrogen or C.sub.1 -C.sub.5 alkyl; R.sub.2 can be hydrogen or a COOR.sub.4 group (wherein R.sub.4 is hydrogen or C.sub.1 -C.sub.5 alkyl), CN, SO.sub.3 H, PO.sub.3 H or a tetrazole group R.sub.3 ; can be a hydrogen or a moiety of formula (II)B'(R'.sub.2,R'.sub.3) (II)wherein: B.sup.1, R.sup.1.sub.2 have the same meanings reported above for B and R.sub.2, R'.sub.3 is H; with the proviso that when A is phenyl, R.sub.